Orexigenic Therapy With Delta-9-tetrahydrocannabinol in Advanced Cancer Patients With Chemosensory Abnormalities - a Pilot Study
Cancer, Anorexia, Taste Disorders
About this trial
This is an interventional treatment trial for Cancer focused on measuring cannabinoids, taste disorders, olfaction disorders, cancer, palliative medicine, caloric intake, appetite, reward, tetrahydrocannabinol/therapeutic use, anorexia/drug therapy, quality of life, chemosensory changes/drug therapy
Eligibility Criteria
Inclusion Criteria: advanced cancer patients (defined as locally recurrent or metastatic) over 18 years old with a decreased food intake for at least 2 weeks (reported by physician or subject) able to complete questionnaires in English able to provide informed consent life expectancy of greater than 2 months (as determined by physician) chemosensory complaint score > 1 Exclusion Criteria: receiving enteral or parenteral feedings allergies or sensitivity to THC and/or sesame seed oil history of substance abuse or psychotic episodes mechanical obstruction of alimentary tract, mouth or nose received chemotherapy in the last 2 weeks received radiation therapy to the head/neck area brain tumor nausea score greater than 5 on ESAS history of tachyarrhythmias, angina pectoris or hypertension current diagnosis of liver impairment use of marijuana within 30 days prior to start of trial
Sites / Locations
- Cross Cancer Institute
- Royal Victoria Hospital
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
1
2